The Lancet Haematology
Fecha de publicación: 1 december 2018
Autores: Oliver Ottmann
Background: Before the advent of tyrosine kinase inhibitor (TKI) therapy, Philadelphia chromosome-positive acute lymphoblastic leukaemia had an exceptionally poor prognosis and was a clear indication for allogeneic haemopoietic stem cell transplantation (HSCT). Adding TKIs to frontline therapy improves survival, with transplantation in paediatric patients increasingly reserved for those with poor response.